DrugBaron

JULY 19, 2022

Despite the current hype around so called “advanced therapies”, which range from gene editing to cell therapies, and the inexorable advance of biologic therapeutics such as monoclonal antibodies, even in 2022 the majority of drugs in development and reaching patients are still small organic molecules.

Small Molecule 100

Small Molecule Drugs DNA Pharma Companies 100

DrugBaron

FEBRUARY 7, 2022

Finding small molecule drugs is much harder than finding a needle in a haystack – discovering the right arrangement of atoms to bind precisely to a protein target to elicit a particular response is a problem of vast dimensionality. Yet the situation with small molecules is even worse.

Small Molecule 100

Small Molecule Synthetic Chemistry Pharma Companies Pharmacokinetics 100

Elrig

APRIL 29, 2024

Srinivasan has led the development of multiple computational pipelines to process data from different next generation sequencing techniques with applications in oncology, genome editing systems including CRISPR-Cas mediated DNA editing, and ADAR-mediated RNA editing. There, I supported AI-enabled DD efforts in their small molecule portfolio.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Vial

FEBRUARY 19, 2024

Can you elaborate on how the platform allows your company to tailor therapy? We can link small molecule drugs to a payload that would enter in the cell and kill it. We have the capability of different types of targets, whether small molecules or antibodies. Ahmed Hamby: We also have a very cool modification.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Pharma Data

OCTOBER 14, 2020

Talking Medicine uses advanced AI to provide pharmaceutical companies with real-time data intelligence. has expanded its product portfolio to include Blueprint, a self-service, scientific visualization and analytics application for small molecule discovery. Dolmatics – U.K.-based based Dotmatics Ltd.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

JUNE 12, 2025

The law made it less likely for pharma companies to pursue more rare disease indications, according to industry groups such as the National Pharmaceutical Council. Known as the pill penalty, the IRA currently makes small molecule drugs eligible for price negotiations after nine years, while biologics are granted 13 years.

Small Molecule 130

Small Molecule Packaging Therapies Pharmacy 130